Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

Barclays lowered the firm’s price target on Novo Nordisk (NVO) to DKK 700 from DKK 900 and keeps an Overweight rating on the shares.Stay Ahead ...

(Reuters) - Danish drugmaker Novo Nordisk said on Monday several hundred counterfeit units of its diabetes drug Ozempic were ...

Pfizer announced on Monday that it is halting development of its oral weight-loss pill after one patient experienced liver ...

Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity is now under attack on multiple fronts, from ...

Scientists at Novo Nordisk in Denmark have applied flow chemistry to enhance the cleavage of oligonucleotides.

Novo Nordisk, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

Caroline Rossmeisl bliver beskrevet som en energisk og skarp kommunikationsprofil. Derudover er hun en nytænker, der ved siden af sit arbejde hos Novo Nordisk har skabt den populære podcast ...

Når Novo Nordisk udvikler digitale løsninger til kronisk syge, er det Sara Said Mosleh, der står i spidsen. Og med sin ...

Camilla Sylvest has moved on from Novo Nordisk after 28 years with the Danish pharma, including more than seven years as EVP ...

Denmark’s benchmark stock index has fallen 21% from its September high, making it the first major European index to enter a bear market as tariff-related risks and a slump for Novo Nordisk A/S ...

Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the Danish drugmaker said on Thursday.